Background:
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: November 2018: The following drug classes/subclass and newly approved agents will be reviewed:

ACNE AGENTS - TOPICAL ACNE AND ROSACEA: Adapeline, Plixda

NARCOTIC ANALGESICS AND COMBINATIONS - N/A: Butalbital

HEMATOLOGICAL AGENTS - WHITE BLOOD CELL STIMULANTS: Fulphila

METABOLIC AGENTS-MISCELLANEOUS - N/A: Galafold

TARGETED IMMUNOMODULATORY BIOLOGICS - NON TUMOR NECROSIS FACTOR INHIBITORS: Ilumya

BETA BLOCKERS & HYDROCHLOROTHIAZIDE COMBINATIONS - N/A: Kapspargo Sprinkle

BINDERS-CHELATORS-ANTIDOTES-OVERDOSE-AGENTS- N/A: Lokelma

HEMATOLOGICAL AGENTS - PLATELETS: Mulpleta

ANTIBIOTICS - TETRACYCLINES: Okebo

LUTEINIZING HORMONE-RELEASING HORMONE AGONISTS-ANTAGONISTS - N/A: Orilissa

CYSTIC FIBROSIS AGENTS - N/A: Orkambi Granule

LAXATIVES-CATHARTICS-STOOL SOFTENERS - N/A: Plenvu

ANTIPERSPIRANTS - N/A: Qbrexza

ANTIRETROVIRALS - COMBINATIONS: Symtuza

CORTICOSTEROIDS-IMMUNE MODULATORS - HEREDITARY ANGIOEDEMA AGENTS: Takhzyro

ONCOLOGICAL AGENTS - ACUTE MYELOGENOUS LEUKEMIA: Tibsovo

RFQ: The RFQ, including UF BPA and UF ADP appendices are attached herein.
There is no pre-proposal teleconference. Rather, questions shall be submitted via e-mail to the Request for Quote (RFQ) Point of Contact stated in Part 2.3, no later than the date stated in Part 2.4. Also, responses to Part 3.4 is required.

POCs: Part 2.3 of the RFQ.
For additional information, search DoD Pharmacy and Therapeutics (P&T) Committee at http://www.health.mil/POD

Bid Protests Not Available